The <scp>PI3K</scp> inhibitor pictilisib and the multikinase inhibitors pazopanib and sorafenib have an impact on Rac1 level and migration of medulloblastoma in vitro-Reference-Cited by-同舟云学术

The PI3K inhibitor pictilisib and the multikinase inhibitors pazopanib and sorafenib have an impact on Rac1 level and migration of medulloblastoma in vitro

Published:2022-11-15 Issue:23 Volume:26 Page:5832-5845
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J Cellular Molecular Medi

Author:

Schoen Leonie F.¹^ORCID,Craveiro Rogerio B.²,Pietsch Torsten³,Moritz Thomas⁴,Troeger Anja⁵,Jordans Silvia¹^ORCID,Dilloo Dagmar¹

Affiliation:

1. Department of Pediatric Hematology and Oncology, Center for Pediatrics University Hospital Bonn Bonn Germany

2. Department of Orthodontics University Hospital RWTH Aachen Aachen Germany

3. Department of Neuropathology University Hospital Bonn Bonn Germany

4. Institute of Experimental Hematology Hannover Medical School Hannover Germany

5. Department of Pediatric Hematology, Oncology and Stem Cell Transplantation University Hospital Regensburg Regensburg Germany

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.17604

Reference59 articles.

1. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study

2. The molecular biology of medulloblastoma metastasis

3. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

4. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis

5. Differential patterns of metastatic dissemination across medulloblastoma subgroups

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “PBT-SCREEN”, a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3;2023-08-25

2. An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma;Journal of Neuro-Oncology;2023-06-24

3. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario;Pharmaceutics;2023-02-16